Trials / Completed
CompletedNCT03087487
Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation
Real-World Comparative Effectiveness Research and Related Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients Using Oral Anti-coagulants
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 466,991 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objectives of this study are to compare the risk of major bleeding and stroke/systemic embolism (SE) events among oral anticoagulant (OAC)-naïve non-valvular atrial fibrillation (NVAF) patients initiating OAC warfarin or apixaban or dabigatran or rivaroxaban treatment.
Conditions
Timeline
- Start date
- 2016-06-01
- Primary completion
- 2023-02-26
- Completion
- 2023-03-08
- First posted
- 2017-03-22
- Last updated
- 2025-06-25
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03087487. Inclusion in this directory is not an endorsement.